A defining feature of mixed connective tissue disease (MCTD) is the presence of antibodies against the U1-ribonucleoprotein (RNP) complex, but other autoantibodies in MCTD have recently been described. Research has also further elucidated the immune responses directed against U1-RNP in humans and in murine models of disease. Hypotheses implicating modified self-antigens and/or infectious agents in the pathogenesis of MCTD have been advanced. Links between the immunologic and clinical phenomena in MCTD are emerging.
Disease classification and natural history of mixed connective tissue disease
The existence of MCTD as a distinct disease entity has been the subject of controversy almost since it was first described by Sharp and colleagues. Smolen and Steiner [1] revisit this topic in a thoughtful editorial. The authors point out the inherent problems with current published criteria for classification of MCTD, and the continuing challenges of classification of the connective tissue diseases in general.
Burdt et al. [2••] describe the long-term outcomes of patients diagnosed with MCTD. They report on the clinical and immunologic status of a cohort of 47 MCTD patients followed for a mean duration of 15 years. Of the patients studied, 37 were initially enrolled prospectively as part of clinical study sponsored by the National Institutes of Health. Overall, a favorable outcome occurred in 62% of patients, whereas 38% had continued active disease or death (see Table 2 ). Immunologically, all patients had antibodies against the U1-70kD polypeptide and most had antibodies against U1-RNA. There was initial epitope spreading or expansion of reactivity against different U1-RNP polypeptides followed later by epitope contraction, and ultimately by the disappearance of U1-RNP peptide reactive antibodies in patients who entered clinical remission.
ies were identified as a risk factor for the development of pulmonary hypertension in this cohort. Nishimaki et al. [3] analyzed the immunologic characteristics of 24 Japanese patients with MCTD complicated by pulmonary hypertension, and reported that anti-U1-RNP, antiendothelial cell and anticardiolipin antibodies were all associated with the development of pulmonary hypertension. McLaughlin et al. [4•] recently reported a promising clinical study on the treatment of pulmonary hypertension. In a series of case studies, they found that patients with secondary pulmonary hypertension, including 14 with connective tissue disease, treated with continuous infusion of prostacyclin, had statistically significant reductions in mean pulmonary artery pressure and increases in cardiac output. Klings et al. [5] report similar favorable results. In the longitudinal MCTD study of Burdt et al. [2••] , pulmonary hypertension was not progressive in all patients; three improved with intensive immunosuppressive therapy and two had sustained remission. examined possible pathogenic mechanisms leading to pulmonary hypertension in MCTD. They reported that purified immunoglobulin (Ig)G anti-U1-RNP antibodies increased surface expression of intercellular adhesion molecule-1 (ICAM-1), leukocyte adhesion molecule-1 (ELAM-1) and major histocompatibility complex class II on pulmonary artery endothelial cell in vitro. These effects persisted when the IgG was pretreated to remove its Fc fragment. This work suggests that anti-U1-RNP antibodies may participate directly in the pathogenesis of pulmonary hypertension and that the mechanism of such action could be independent of Fc receptor mediated events.
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Other autoantibodies in mixed connective tissue disease
A number of recent studies have described autoantibodies other than anti-U1-RNP in MCTD. Skriner et al. [7] performed epitope mapping studies on the A2 protein of the heterogeneous nuclear ribonucleoprotein complex (hnRNP-A2) and observed that sera from patients with MCTD were directed against an epitope distinct from that recognized by sera from patients with either rheumatoid arthritis or SLE.
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Disease classification and outcome
Immunogenetics distinctive and find association of MCTD with HLA-DR4 Anti-U1-70kD & anti-hnRNP antibodies characterized in MCTD Long-term outcome of MCTD defined in large North American population Pulmonary hypertension in MCTD Anticardiolipin antibodies associated with pulmonary hypertension Pulmonary hypertension defined as the primary disease-associated cause of death Continuous infusion of prostacyclin may benefit pulmonary hypertension in MCTD U1-RNP implicated to play a direct role in pathogenesis of pulmonary hypertension
New findings about autoantibodies in MCTD Anti-hnRNP-A2 antibody subset specific for MCTD Anticardiolipin antibodies beta-2-glycoprotein I independent in MCTD Anti-fibrillin-1 present in some patients with MCTD Anti-RNA polymerase antibodies in scleroderma but not MCTD Anti-U1-RNP antibodies Select portions U1-RNP antigen implicated as target of immune recognition Major histocompatibility complex genes control autoantibody production in murine models T-cell responses directed against U1-70kD T-cell response to U1-70kD antigen defined in humans Structure of U1-70kD-specific T-cell receptor determined Murine model studies define role for T-cell receptor alpha/beta-and gamma/delta-positive cells U1-70kD peptides, modified self antigens and molecular mimicry Apoptotic and oxidative modification of U1-70kD may play a role in autoimmunity Antibodies against apoptotically modified U1-70kD associated with skin disease Antibodies against oxidatively modified U1-70kD associated with Raynaud phenomenon Lupuslike illness induced in mice with fragment of B polypeptide, (with homology to Epstein-Barr virus) In response to the report of Konatireddy et al. [8] , Mendoça et al. [9] also found that anticardiolipin antibodies in MCTD do not seem to be associated with the antiphospholipid syndrome. Additionally, they report that most anticardiolipin antibodies in MCTD sera are beta-2-glycoprotein I independent, and propose that this may explain the absence of associated clotting events.
Tan et al. [10•] described a comprehensive survey of rheumatic disease patients, examining sera for the presence of antibodies reactive with a recombinant fusion protein for the human fibrillin-1 gene. The fibrillin-1 gene has been found to be duplicated in a spontaneously occurring murine model of systemic sclerosis, the tight skin mouse. Antibodies against fibrillin-1, a main component of microfibrils in the extracellular matrix of skin, are a characteristic feature of the tight skin mouse. They report that whereas the presence of the antibody in patients was most strongly associated with the diffuse form of systemic sclerosis, it was also significantly increased in frequency among patients with MCTD.
Chang et al. [11] performed a comprehensive survey of US patients with MCTD, SLE, diffuse systemic sclerosis (SSc) and limited SSc for the presence of antibodies against RNA polymerases I, II, and III using a quantitative assay. They found that antibodies against RNA polymerases could be detected in 22% of patients with the diffuse form of SSc, 2% of patients with the limited form of SSc, and 2% of patients with SLE, whereas they did not occur in any of the 49 MCTD patients tested.
U1-RNP autoantibodies in mixed connective tissue diseases
In animal models, immunization with individual U1-RNP proteins or peptides can induce spreading of the immune response to other components of the U1-RNP [12••,13,14] . These data implicate the U1-RNP particle itself as an eventual target of immune recognition, but demonstrate that the initiating immune stimulus need not be the entire U1-RNP.
Significant advances have been made in defining the genetics of autoantibody production using murine models of lupus; these are the subjects of a recent review [15] . In one particularly noteworthy study, Vyse et al. [16•] performed a genome-wide screen of lupus prone F1 hybrid New Zealand Black X New Zealand White mice backcrossed to map dominant genetic loci linked to disease traits, including autoantibody production. They found that the production of different sets of nephrogenic autoantibodies were differentially regulated by the murine major histocompatibility genes, H2z and H2d. These findings are relevant to MCTD in view of the fact that antibody production against U1-70kD and U1-RNA in MCTD are associated with HLA-DR4 and differ from the HLA genes found to be associated with the production of anti-DNA or anti-Ro antibody in SLE [1] .
The titers of individual U1-RNP antibodies have been evaluated as markers of disease activity. Using activity scales derived from lupus research, anti-U1-RNA titers have correlated with activity [17] and anti-U1-70kD titers have not [18] .
Advances in epitope mapping of U1-RNP determinants have been reported. Hoet et al. [19] find that immunoglobulin light chain plays a major role in determining the specificity of anti-U1-RNA antibodies generated from a human combinatorial IgG library. Their antibodies, derived from a patient who expressed anti-U1-RNA, recognized stemloop II of U1-RNA with high avidity (Fig. 1) . Henriksson et al. [20] used mutated Drosophila melanogaster U1-70kD proteins as antigens in a novel approach to map the epitopes recognized by human U1-70kD autoantibodies. They report that amino acids at position 119-126 are central for antibody recognition, and that amino acid residue 125 is crucial. Interestingly, these amino acids are positioned at an exposed area in the end of an alpha helix in the RNA binding region. Kawahata et al. [21] generated mice transgenic for the human A polypeptide to examine the role of this U1-RNP antigen in autoimmunity. They found that while the mice generated were tolerant to the antigen, they could elicit an immune response using adoptive transfer of autoreactive cells. Using this method, they were able to elicit a strong immune response, including the generation of autoantibodies and the development of glomerulonephritis. In this model, immunity to the A polypeptide could elicit spreading of the immune response to the U1-70kD polypeptide. Finally, they showed that the antibody response was antigen-specific and T-cell-dependent.
T-cell immunity against U1-RNP polypeptide antigens
Like the humoral response, the cell-mediated immune response to U1-RNP appears to be antigen-driven. Talken et al. [22] studied the structure of T-cell receptors on human T-cell clones specific for the U1-70kD polypeptide, which were derived from MCTD patients. Common structural motifs were found within the third complementarity-determining regions (CDR3) of the U1-70kD-reactive TCR alpha chains from these patients. These results are consistent with an antigen driven immune process where a limited number of dominant U1-70kD epitopes select T cells with a limited number of TCR motifs for expansion.
Craft et al.
[12••] completed a series of seminal studies characterizing the murine immune response to U1-RNP polypeptide in normal and autoimmune MRL/lpr mice. They have shown that alpha/beta expressing T cells are central to the anti-U1-RNP immune response but have also shown that gamma/delta T cells play a key regulatory role in the response, particularly lacking alpha/beta T cell in mice rendered deficient of such cells using the technique of homologous recombination or targeted gene disruption (so called "knock-out" mice).
Role of the U1-70kD peptide in the anti-U1-RNP immune response
One hypothesis suggests that modified forms of selfantigens may act as immunogens in anti-RNP responses. The U1-70kD peptide has become an especially intriguing potential immunogen because it alone is known to be susceptible to multiple forms of antigen modification that have been linked with different rheumatic diseases. Apoptotic modification of U1-70kD has been linked to lupus [23] [24] [25] . Metal-catalyzed oxidative modification of U1-70kD (as with the autoantigens topoisomerase I, anti-RNA polymerase, Th/To, and UBF/Nor90) has been linked to scleroderma [26] . Greidinger et al. [27] report that antibodies to both modified forms of U1-70kD have clinical significance in humans. In a study of 27 subjects with anti-U1-70kD antibodies, high relative recognition of apoptotic U1-70kD correlated with the presence of lupus skin disease, whereas high relative recognition of oxidative U1-70kD correlated with the presence of Raynaud phenomenon. This is the first report that has linked immunity to modified forms of RNP antigens with specific clinical disease phenotypes.
Infectious agents in the etiopathogenesis of disease
Curtis et al. [28] report that recombinant cytomegalovirus glycoprotein gB (UL55) induces an IgG autoantibody response to the U1-70kD peptide when injected into both autoimmune MRL/Mp-lpr and normal mice strains. This work is supportive of the possibility that microbial agents could initiate an immune response against U1-RNP self antigens.
Harley, James and colleagues [14, 29] published additional work expanding on their highly original studies characterizing the evolution of the humoral immune response against the B/B' polypeptide components of the spliceosome. They have previously found that the initial human antibody response to B/B' is directed against the peptide PPPGMRPP. They now report that immunization of inbred strains of mice with this peptide sequence PPPGMRPP in adjuvant can elicit a lupus-like syndrome [14, 30] . Furthermore, they report that some mice strains had intramolecular spreading to other determinants, including the development of anti-U1-RNP antibodies. Based on structural homology of PPGMRPP to the Epstein-Barr virus (EBV) and epidemiologic evidence suggesting an association between EBV infectious and SLE in children, they have suggested that there may be causal link in humans between EBV infection and the generation of anti-B/B' antibodies [31, 32] .
Conclusions
Pulmonary hypertension stands out as the major cause of death in MCTD. Most patients with MCTD who do not develop pulmonary hypertension have selflimited disease. Additional studies are needed to identify MCTD patients who are at risk for adverse outcomes, and to determine optimal treatment approaches. Some reports are beginning to forge links between the immunologic phenomena in MCTD and the clinical expression of disease. Clinical manifestations of MCTD such as pulmonary hypertension, lupus skin disease, and Raynaud phenomenon have been associated with antiphospholipid antibodies and antibodies to modified U1-70kD peptides. The immune phenomena in MCTD appear to be antigendriven. Both modified self antigens and infectious agents are being investigated as possible etiologic agents. Increased understanding of the relation of the immune events in MCTD to its pathogenesis will lead to improvements in disease management.
